NCT06389214View on ClinicalTrials.gov

A Clinical Trial to Assess the Efficacy and Safety of Subjects With Dry Eye Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

April 9, 2024

Primary Completion Date

June 11, 2024

Study Completion Date

June 11, 2024

Conditions
Dry Eye Disease
Interventions
DRUG

Reproxalap Ophthalmic Solution (0.25%)

Reproxalap Ophthalmic Solution (0.25%) administered six times over two consecutive days

DRUG

Vehicle Ophthalmic Solution

Vehicle Ophthalmic Solution administered six times over two consecutive days

Trial Locations (1)

Unknown

Cliantha Research, Mississauga

Sponsors
All Listed Sponsors
lead

Aldeyra Therapeutics, Inc.

INDUSTRY

NCT06389214 - A Clinical Trial to Assess the Efficacy and Safety of Subjects With Dry Eye Disease | Biotech Hunter | Biotech Hunter